Revolution Medicines, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 07, 2023 at 02:40 am IST
Share
Revolution Medicines, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 108.43 million compared to USD 73.33 million a year ago. Basic loss per share from continuing operations was USD 0.99 compared to USD 0.87 a year ago.
For the nine months, revenue was USD 10.84 million compared to USD 20.05 million a year ago. Net loss was USD 274.83 million compared to USD 192.2 million a year ago. Basic loss per share from continuing operations was USD 2.65 compared to USD 2.47 a year ago.
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Companyâs research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Companyâs RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.
REVOLUTION MEDICINES, INC. 
